DXCM Stock Recent News

I initially rated DexCom's stock as sell due to competition and GLP-1 threats, but surprising 1Q25 growth prompts an upgrade to hold. DXCM posted better than expected growth figures in 1Q25, establishing a reaccelerating trend in growth for the company. However, DXCM's competitor product, Abbott's Libre Freestyle, has been growing faster despite larger sales.

DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.

Nasdaq jumps as Dexcom, Palantir, and ON Semi soar. Jobs report beats forecasts, easing inflation fears and driving US stock market optimism.

Dexcom, the maker of glucose monitors for patients with diabetes, reports a strong first quarter.

Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock market. While it's a perfectly human reaction to volatility, it's a tendency investors should avoid.

DexCom, Inc. (NASDAQ:DXCM ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants Sean Christensen - VP, Finance & IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & Chief Accounting Officer Jacob Leach - EVP & COO Conference Call Participants Matt Taylor - Jefferies Robbie Marcus - JPMorgan Danielle Antalffy - UBS Jeff Johnson - Baird Jayson Bedford - Raymond James Travis Steed - Bank of America Merrill Lynch Matt O'Brien - Piper Sandler Marie Thibault - BTIG Joanne Wuensch - Citibank Michael Polark - Wolfe Research Margaret Andrew - William Blair Mike Kratky - Leerink Partners Colin Clark - Stifel, Nicolaus & Company Issie Kirby - Redburn Bill Plovanic - Canaccord Chris Pasquale - Nephron Steve Lichtman - Oppenheimer & Co. Matt Miksic - Barclays Anthony Petrone - Mizuho Group Operator Welcome to the DexCom First Quarter 2025 Earnings Release Conference Call. My name is Louella, and I will be your operator for today's call.

Although the revenue and EPS for DexCom (DXCM) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

DexCom (DXCM) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.33 per share. This compares to earnings of $0.32 per share a year ago.

Medical device maker Dexcom beat first-quarter sales estimates helped by strong demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program.